Peter Greenleaf, president of MedImmune, the Gaithersburg, Maryland-based global biologics arm of AstraZeneca, addressed many of the challenges and growth opportunities for Maryland biotech companies at today's MdBio Leadership Series breakfast, hosted by the Tech Council of Maryland (TCM).
"Maryland is a hotbed of activity in the biotech sector, so changes taking place in the industry -- related to competitive threats and growth opportunities -- will no doubt have a big impact on businesses based in our state," said Art Jacoby, TCM's CEO. "Peter's remarks this morning provided valuable insight -- from not only his role as president of MedImmune, but from the perspective as chairman of the Maryland Venture Fund Authority -- into the changes taking place in the biotech market and how companies at all stages can position themselves for success."